Balance Sheet
Accounts PayablesAccumulated ExpensesAssetsCash & Current InvestmentsCash & EquivalentsCommon EquityCurrent AssetsGoodwill & IntangiblesIntangiblesInventoryLiabilities and Shareholders EquityNon-Current AssetsNon-Current DebtNon-Current Deferred Tax LiabilityOperating LeasesOther Accumulated ExpensesOther Non-Current AssetsOther Non-Current LiabilitiesPayablesPrepaid AssetsProperty, Plant & Equipment (Net)ReceivablesRetained EarningsShareholder's EquityShort-term InvestmentsTotal Current LiabilitiesTotal DebtTotal LiabilitiesTotal Non-Current LiabilitiesTreasury Shares
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Coherus Oncology (CHRS) Operating Leases (2019 - 2025)

Coherus Oncology (CHRS) has disclosed Operating Leases for 7 consecutive years, with $1.5 million as the latest value for Q4 2025.

  • Quarterly Operating Leases fell 55.66% to $1.5 million in Q4 2025 from the year-ago period, while the trailing twelve-month figure was $1.5 million through Dec 2025, down 55.66% year-over-year, with the annual reading at $1.5 million for FY2025, 55.66% down from the prior year.
  • Operating Leases hit $1.5 million in Q4 2025 for Coherus Oncology, down from $1.9 million in the prior quarter.
  • In the past five years, Operating Leases ranged from a high of $9.2 million in Q1 2021 to a low of $1.4 million in Q3 2023.
  • Historically, Operating Leases has averaged $4.8 million across 5 years, with a median of $4.4 million in 2024.
  • Biggest five-year swings in Operating Leases: plummeted 76.55% in 2023 and later skyrocketed 160.24% in 2024.
  • Year by year, Operating Leases stood at $7.3 million in 2021, then crashed by 30.41% to $5.0 million in 2022, then increased by 5.59% to $5.3 million in 2023, then tumbled by 38.33% to $3.3 million in 2024, then crashed by 55.66% to $1.5 million in 2025.
  • Business Quant data shows Operating Leases for CHRS at $1.5 million in Q4 2025, $1.9 million in Q3 2025, and $2.4 million in Q2 2025.